Rahnasto-Rilla M - Search Results

1

CYP2A6: genetics, structure, regulation, and function.

Raunio H, Rahnasto-Rilla M. Raunio H, et al. Drug Metabol Drug Interact. 2012 May 5;27(2):73-88. doi: 10.1515/dmdi-2012-0001. Drug Metabol Drug Interact. 2012. PMID: 22706231 Review.

2

Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver.

Abu-Bakar A, Hakkola J, Juvonen R, Rahnasto-Rilla M, Raunio H, Lang MA. Abu-Bakar A, et al. Curr Drug Metab. 2013 Jan;14(1):137-50. Curr Drug Metab. 2013. PMID: 22497566 Review.

3

Rational design of novel CYP2A6 inhibitors.

Tani N, Juvonen RO, Raunio H, Fashe M, Leppänen J, Zhao B, Tyndale RF, Rahnasto-Rilla M. Tani N, et al. Bioorg Med Chem. 2014 Dec 1;22(23):6655-6664. doi: 10.1016/j.bmc.2014.10.001. Epub 2014 Oct 13. Bioorg Med Chem. 2014. PMID: 25458499

4

Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes.

Raunio H, Juvonen RO, Poso A, Lahtela-Kakkonen M, Rahnasto-Rilla M. Raunio H, et al. Drug Metab Lett. 2016;10(1):56-64. doi: 10.2174/1872312810666151204002456. Drug Metab Lett. 2016. PMID: 26648056

5

Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.

Tani N, Rahnasto-Rilla M, Wittekindt C, Salminen KA, Ritvanen A, Ollakka R, Koskiranta J, Raunio H, Juvonen RO. Tani N, et al. Eur J Med Chem. 2012 Jan;47(1):270-7. doi: 10.1016/j.ejmech.2011.10.053. Epub 2011 Nov 6. Eur J Med Chem. 2012. PMID: 22100140

6

Interactions of inhibitor molecules with the human CYP2E1 enzyme active site.

Martikainen LE, Rahnasto-Rilla M, Neshybova S, Lahtela-Kakkonen M, Raunio H, Juvonen RO. Martikainen LE, et al. Eur J Pharm Sci. 2012 Dec 18;47(5):996-1005. doi: 10.1016/j.ejps.2012.09.018. Epub 2012 Oct 13. Eur J Pharm Sci. 2012. PMID: 23069620

7

Time-Dependent Inhibition of CYP2C19 by Isoquinoline Alkaloids: In Vitro and In Silico Analysis.

Salminen KA, Rahnasto-Rilla M, Väänänen R, Imming P, Meyer A, Horling A, Poso A, Laitinen T, Raunio H, Lahtela-Kakkonen M. Salminen KA, et al. Drug Metab Dispos. 2015 Dec;43(12):1891-904. doi: 10.1124/dmd.115.065755. Epub 2015 Sep 23. Drug Metab Dispos. 2015. PMID: 26400396

8

Functional impact of cytochrome P450 3A (CYP3A) missense variants in cattle.

Giantin M, Rahnasto-Rilla M, Tolosi R, Lucatello L, Pauletto M, Guerra G, Pezzato F, Lopparelli RM, Merlanti R, Carnier P, Capolongo F, Honkakoski P, Dacasto M. Giantin M, et al. Among authors: rahnasto rilla m. Sci Rep. 2019 Dec 23;9(1):19672. doi: 10.1038/s41598-019-56271-8. Sci Rep. 2019. PMID: 31873175 Free PMC article.

9

Quantitative insights for the design of substrate-based SIRT1 inhibitors.

Kokkonen P, Mellini P, Nyrhilä O, Rahnasto-Rilla M, Suuronen T, Kiviranta P, Huhtiniemi T, Poso A, Jarho E, Lahtela-Kakkonen M. Kokkonen P, et al. Eur J Pharm Sci. 2014 Aug 1;59:12-9. doi: 10.1016/j.ejps.2014.04.003. Epub 2014 Apr 18. Eur J Pharm Sci. 2014. PMID: 24747578

10

Studying SIRT6 regulation using H3K56 based substrate and small molecules.

Kokkonen P, Rahnasto-Rilla M, Mellini P, Jarho E, Lahtela-Kakkonen M, Kokkola T. Kokkonen P, et al. Eur J Pharm Sci. 2014 Oct 15;63:71-6. doi: 10.1016/j.ejps.2014.06.015. Epub 2014 Jul 6. Eur J Pharm Sci. 2014. PMID: 25004411

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page